| abstract |
IT REFERS TO A METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF LEUKOCYTE THAT INCLUDES ADMINISTERING AN EFFECTIVE AMOUNT OF AT LEAST ONE DUAL INHIBITOR OF PHOSPHODIESTERASE 7 AND PHOSPHODIESTERASE 4 (PDE7-PDE4 IN THE ICSHUAL IN ICSHOS PDE50 IN THE ICSHOS4) OF PDE7 AND PDE4 IS LESS THAN 20 MICROMOLARS AND THE IC50 IN AN INHIBITION TEST PDE3 IS AT LEAST 10 TIMES GREATER THAN THE IC50 OF THE COMPOUND IN THE PDE7 TEST. PREFERRED COMPOUNDS ARE ETHYL ESTER OF 4-METHYL-2 - [[6- (METHYLAMINE) -9 - [[4- (METHYLSULFONIL) PHENYL] METHYL] -9H-PURIN-2-IL] AMINO] -5-THIAZOLCARBOXYL ACID 4-METHYL-2 ACID ETHYL ESTER - [[9 - [[4- (METHYLSULFONIL) PHENYL] METHYL] -6 - [[[4- (METHYLSULFONYL) PHENYL] METHYL] AMINO] -9H-PURIN-2-IL ] AMINO] -5-THIAZOLCARBOXYL, AMONG OTHERS. DUAL INHIBITORS OF PDE7 AND PDE4 ARE USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LEUKOCYTE ACTIVATION SUCH AS RHEUMATOID ARTHRITIS, PSORIASIS, ASTHMA |